Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 10/30/24
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with GlioblastomaGlobeNewsWire • 10/28/24
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with GlioblastomaGlobeNewsWire • 09/16/24
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)GlobeNewsWire • 08/26/24
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaGlobeNewsWire • 08/14/24
Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONEGlobeNewsWire • 07/19/24
Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024GlobeNewsWire • 05/22/24
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024GlobeNewsWire • 04/23/24
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024GlobeNewsWire • 04/03/24
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024GlobeNewsWire • 03/05/24
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024PRNewsWire • 01/23/24
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaPRNewsWire • 01/08/24
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaPRNewsWire • 12/11/23
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023PRNewsWire • 11/30/23
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License AgreementPRNewsWire • 10/31/23
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor ConferencePRNewsWire • 10/10/23
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaPRNewsWire • 09/25/23
Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health FairPRNewsWire • 09/13/23